Brainsway Ltd (IL:BWAY)
TASE:BWAY
Want to see IL:BWAY full AI Analyst Report?
BWAY Stock Chart & Stats
3718.00
0.01(0.06%)
At close: 4:00 PM EST
3718.00
0.01(0.06%)
Day’s Range― - ―
52-Week Range1,810.00 - 5,123.00
Previous CloseN/A
Volume32.24K
Average Volume (3M)85.46K
Market Cap
₪1.76B
Enterprise Value548.02M
Total Cash (Recent Filing)₪69.13M
Total Debt (Recent Filing)₪6.82M
Price to Earnings (P/E)58.4
Beta0.12
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.20
Shares Outstanding40,040,730
10 Day Avg. Volume88,081
30 Day Avg. Volume85,462
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)5.11
Price to Sales (P/S)6.62
P/FCF Ratio21.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Installed Base & Revenue GrowthRapid unit placements and strong top-line growth reflect durable demand and expanding clinical adoption. A larger installed base increases recurring consumable, service and utilization revenue streams and improves multi‑year visibility into replacement/consumable tail revenue, supporting sustainable growth.
Sustained Profitability And Margin ExpansionConsistent quarterly profitability and expanding operating income reflect scalable unit economics and durable gross margins (mid‑70% historically). This operating leverage provides structural capacity to fund growth, reduce reliance on external capital, and improve free cash flow generation over the medium term.
Strong Balance Sheet & Cash GenerationLarge cash reserves and a material improvement in operating cash flow give the company financial flexibility to invest in commercialization, R&D and strategic minority clinic stakes without near‑term dilution. Conservative historical leverage further reduces refinancing risk and supports execution of multi‑year initiatives.
Bears Say
Reimbursement DependenceCommercial upside for new protocols and faster treatment paths hinges on payer policy adoption. Reimbursement timing and coverage decisions are structural constraints that directly affect utilization, system placement economics and recurring revenue; delays or limited coverage could materially slow durable growth.
Early-stage Neurolief ExposureBrainsWay’s upside from Neurolief/ProlivRx is tied to milestone‑based funding and the third party’s commercial execution. This creates conditional, execution‑dependent exposure rather than guaranteed revenue, introducing diluted optionality and commercialization risk that could limit realized long‑term benefits.
Rising Operating ExpensesManagement is increasing S&M, R&D and G&A to accelerate adoption. If revenue or reimbursement progress lags, sustained higher operating spend could compress margins and free cash flow. Balancing investment for scale against margin sustainability is a structural execution risk over coming quarters.
Brainsway News
BWAY FAQ
What was Brainsway Ltd’s price range in the past 12 months?
Brainsway Ltd lowest stock price was 1810.00 and its highest was 5123.00 in the past 12 months.
What is Brainsway Ltd’s market cap?
Brainsway Ltd’s market cap is ₪1.76B.
When is Brainsway Ltd’s upcoming earnings report date?
Brainsway Ltd’s upcoming earnings report date is Aug 12, 2026 which is in 83 days.
How were Brainsway Ltd’s earnings last quarter?
Brainsway Ltd released its earnings results on May 13, 2026. The company reported 17.8 earnings per share for the quarter, beating the consensus estimate of N/A by 17.8.
Is Brainsway Ltd overvalued?
According to Wall Street analysts Brainsway Ltd’s price is currently Overvalued.
Does Brainsway Ltd pay dividends?
Brainsway Ltd does not currently pay dividends.
What is Brainsway Ltd’s EPS estimate?
Brainsway Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Brainsway Ltd have?
Brainsway Ltd has 40,040,730 shares outstanding.
What happened to Brainsway Ltd’s price movement after its last earnings report?
Brainsway Ltd reported an EPS of 17.8 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.277%.
Which hedge fund is a major shareholder of Brainsway Ltd?
Currently, no hedge funds are holding shares in IL:BWAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Brainsway Ltd
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
BWAY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong operational quarter with broad revenue and profitability gains, meaningful clinical and payer progress (notably SWIFT), a growing installed base and a solid cash position. Strategic investments (minority clinic stakes and Neurolief funding) and international momentum support long-term growth, but the company is making tradeoffs by increasing operating investments and remains partially dependent on payer coverage and milestone-driven commercialization paths. Overall, positives—robust top-line growth, margin expansion, RPO improvement and clinical validation—materially outweigh the risks, though execution and reimbursement timing will be critical to sustain momentum.View all IL:BWAY earnings summaries